Mooren-type hepatitis C virus-associated corneal ulceration.
BACKGROUND
Two patients with bilateral Mooren-type ulcers had underlying chronic hepatitis C virus (HCV) infection. Both patients also had chronic, pruritic dermatitis, which in one patient was diagnosed as hidradenitis suppurativa.


METHODS
Serum from the first patient and serum, conjunctiva, and liver from the second patient were analyzed for HCV genomic RNA using the reverse transcriptase-polymerase chain reaction. Serum anti-HCV antibodies were monitored with a commercially available second-generation test. Liver and conjunctival biopsies were evaluated histopathologically.


RESULTS
Liver biopsy showed severe hepatitis in the first patient, but normal liver tissue in the second. Hepatitis C virus genomic RNA was detected in the serum of both patients. In the first patient, the virus was detected 4 months after completion of interferon alfa-2b treatment for chronic active hepatitis. In the second patient, HCV genomic RNA was detected in serum, but not in conjunctiva or liver tissue. Hepatitis C virus could not be detected in the serum of the second patient after 2 weeks of interferon alfa-2b treatment. Both patients had serum anti-HCV antibodies. In case 1, there was a marked improvement in the corneal disease during and after 6 months of interferon alfa-2b treatment for chronic active hepatitis that paralleled a return of serum liver enzyme levels to the normal range. In the second patient, the corneal disease improved after 6 weeks of interferon alfa-2b treatment, but abruptly worsened when the patient discontinued therapy. The corneal disease improved again after interferon alfa-2b was reinstituted.


CONCLUSIONS
Chronic HCV virus infection is associated with Mooren-type peripheral ulcerative keratitis. All patients with Mooren-type ulcers should be tested for evidence of HCV infection in consultation with a liver specialist. Even when improvement is obtained with interferon alfa-2b treatment, however, continued follow-up is important because relapse is common and repeat treatment may be effective.
Wilson
S E
SE
Department of Ophthalmology, University of Texas Southwestern Medical Center at Dallas 75235.
Lee
W M
WM
Murakami
C
C
Weng
J
J
Moninger
G A
GA
D000328:Adult; D001483:Base Sequence; D003228:Conjunctiva / Q000382:microbiology / Q000473:pathology; D003320:Corneal Ulcer / Q000382:microbiology* / Q000473:pathology / Q000628:therapy; D017931:DNA Primers; D004587:Electrophoresis, Agar Gel; D015828:Eye Infections, Viral / Q000150:complications* / Q000473:pathology / Q000628:therapy; D005260:Female; D016174:Hepacivirus / Q000235:genetics / Q000276:immunology; D006508:Hepatitis Antibodies / Q000276:immunology; D006526:Hepatitis C / Q000150:complications* / Q000473:pathology / Q000628:therapy; D018937:Hepatitis C Antibodies; D017497:Hidradenitis Suppurativa / Q000150:complications / Q000473:pathology; D006801:Humans; D000077190:Interferon alpha-2; D016898:Interferon-alpha / Q000627:therapeutic use; D008099:Liver / Q000382:microbiology / Q000473:pathology; D008297:Male; D008875:Middle Aged; D008969:Molecular Sequence Data; D016133:Polymerase Chain Reaction; D012367:RNA, Viral / Q000032:analysis; D011994:Recombinant Proteins
D017931:DNA Primers; D006508:Hepatitis Antibodies; D018937:Hepatitis C Antibodies; D000077190:Interferon alpha-2; D016898:Interferon-alpha; D012367:RNA, Viral; D011994:Recombinant Proteins